Answer
Praxbind (idarucizumab) is restricted to hospital use and administered intravenously at a recommended dose of 5 g (two 2.5 g/50 mL vials), as two consecutive infusions lasting 5–10 minutes each or as a bolus injection.
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §4.2 Posology and method of administration · Version 12Document updated
Sources checked